SEASON 3, EPISODE 13 - Torbjørn Furuseth, MD - Is it Time for Digital Biomarkers?
Is it time for digital biomarkers? Our guest today is Torbjørn Furuseth of DoMore Diagnostics. Predictive and prognostic algorithms may be the crown jewel of digital pathology, enhancing our value as pathologists to be the chief purveyor of this information in assisting doctors and patients. We discuss the unmet need in oncology, particularly in colon cancer, to develop predictive and prognostic tools to guide therapy. We also explore the advantages of digital pathology over molecular tools and how these methodologies can be used together in some cases. What goes into the development and validation of such tools? Why might new and innovative CPT codes be necessary to encourage innovation in digital pathology? How do reimbursement challenges affect the innovation pipeline for digital pathology? And in the increasingly global marketplace, what considerations must we take into account to help patients across the world? Torbjørn is the CEO and Co-Founder of DoMore Diagnostics, a leader in AI and deep learning precision diagnostics for digital pathology, focused on outcome prediction to personalize cancer treatment. He is a medical doctor with broad experience in life sciences and oncology. After practicing as a physician in radiology and sports medicine, he transitioned into business and management as a consultant at McKinsey & Company, where he served several pharma and healthcare clients. Following McKinsey, he has held multiple leadership positions in Norwegian life science companies and served as CFO at two immuno-oncology companies. Torbjørn’s vision is to play an important role in an important innovation.